South Korean conglomerate SK Holdings jumped decidedly into contract manufacturing a couple of years ago with deals for API plants in Ireland and the U.S. Now, it is rolling those into a group that includes its plant in South Korea in hopes of becoming a key player in the business.
The drugmaker over the weekend said it is merging its SK biotek in Korea and SK biotek in Ireland along with Ampac Fine Chemicals in the U.S. to form SK Pharmteco, the Korea Biomedical Review reports. It has named Aslam Malik, CEO of Ampac, to head the CDMO and established its headquarters in Sacramento, California.
SK Pharmteco believes the integration will help it attract customers and sharpen its competitive edge, the report said.
SK, which had been an ingredient supplier to Bristol-Myers Squibb, last year snapped up a BMS plant in Swords, Ireland, with 300 employees for an undisclosed sum. Under the deal, SK agreed to continue to produce the products BMS made at the plant, which included the API for BMS and Pfizer’s anticoagulant Eliquis.
A month later, it closed a deal to buy Ampac, a U.S. contract manufacturer that makes APIs for controlled substances, among other things. That gave SK a network of U.S. facilities in Rancho Cordova and El Dorado Hills in California; La Porte, Texas; and Petersburg, Virginia.
By Eric Palmer
Source: Fierce Pharma
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.